Corcept Therapeutics Inc (CORT)
24.52
-0.54
(-2.15%)
USD |
NASDAQ |
May 03, 16:00
24.98
+0.46
(+1.88%)
After-Hours: 20:00
Corcept Therapeutics Enterprise Value: 2.170B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 2.170B |
| May 02, 2024 | 2.226B |
| May 01, 2024 | 2.104B |
| April 30, 2024 | 2.046B |
| April 29, 2024 | 2.051B |
| April 26, 2024 | 1.992B |
| April 25, 2024 | 1.931B |
| April 24, 2024 | 1.959B |
| April 23, 2024 | 2.013B |
| April 22, 2024 | 1.940B |
| April 19, 2024 | 2.008B |
| April 18, 2024 | 1.977B |
| April 17, 2024 | 2.013B |
| April 16, 2024 | 2.053B |
| April 15, 2024 | 2.028B |
| April 12, 2024 | 2.065B |
| April 11, 2024 | 2.098B |
| April 10, 2024 | 2.095B |
| April 09, 2024 | 2.267B |
| April 08, 2024 | 2.140B |
| April 05, 2024 | 2.240B |
| April 04, 2024 | 2.225B |
| April 03, 2024 | 2.287B |
| April 02, 2024 | 2.257B |
| April 01, 2024 | 2.296B |
| Date | Value |
|---|---|
| March 28, 2024 | 2.239B |
| March 27, 2024 | 2.253B |
| March 26, 2024 | 2.194B |
| March 25, 2024 | 2.185B |
| March 22, 2024 | 2.168B |
| March 21, 2024 | 2.194B |
| March 20, 2024 | 2.159B |
| March 19, 2024 | 2.142B |
| March 18, 2024 | 2.148B |
| March 15, 2024 | 2.036B |
| March 14, 2024 | 2.082B |
| March 13, 2024 | 2.137B |
| March 12, 2024 | 2.164B |
| March 11, 2024 | 2.090B |
| March 08, 2024 | 2.079B |
| March 07, 2024 | 2.052B |
| March 06, 2024 | 2.016B |
| March 05, 2024 | 2.031B |
| March 04, 2024 | 2.132B |
| March 01, 2024 | 2.122B |
| February 29, 2024 | 2.064B |
| February 28, 2024 | 2.085B |
| February 27, 2024 | 2.132B |
| February 26, 2024 | 2.026B |
| February 23, 2024 | 1.956B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
882.59M
Minimum
Mar 16 2020
3.127B
Maximum
Feb 08 2021
1.928B
Average
1.977B
Median
Apr 18 2024
Enterprise Value Benchmarks
| Ultragenyx Pharmaceutical Inc | 2.943B |
| Alnylam Pharmaceuticals Inc | 17.92B |
| Catalyst Pharmaceuticals Inc | 1.597B |
| United Therapeutics Corp | 9.534B |
| XOMA Corp | 258.75M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.36M |
| Revenue (Quarterly) | 135.40M |
| Total Expenses (Quarterly) | 103.74M |
| EPS Diluted (Quarterly) | 0.28 |
| Gross Profit Margin (Quarterly) | 98.61% |
| Profit Margin (Quarterly) | 23.16% |
| Earnings Yield | 3.87% |
| Operating Earnings Yield | 3.92% |
| Normalized Earnings Yield | 3.874 |